The evidence doesn't support a link between administration of hepatitis B (HPB) vaccine and demyelinating disorders, such as multiple sclerosis (MS) and Guillain-Barré syndrome, so no change in immunization policy is warranted, according to an Institute of Medicine (IOM) report.
Employers Face Barriers With Adopting Biosimilars
March 1st 2022Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.